ClinicalTrials.gg
Not yet recruitingNCT07941518REAL-LAUGHUpdated Nov 17, 2026

Real-world Evidence With Long-Acting User-optimized Growth Hormone Therapy in Pediatric Growth Hormone Deficiency

An observational study in Pediatric Growth Hormone Deficiency, sponsored by Fundació Sant Joan de Déu. Not yet recruiting at 5 sites in Spain. Open to participants aged 3 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Fundació Sant Joan de Déu · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
110
Ages
3 Years to 16 Years
Sex
All
01

Study summary

The REAL-LAUGH study will compare changes in body composition and other health outcomes in children and adolescents with growth hormone deficiency who start weekly or daily growth hormone treatment in routine clinical practice in Spain.

Approximately 110 participants aged 3 to 16 years will be enrolled: 55 receiving weekly long-acting growth hormone and 55 receiving daily recombinant human growth hormone. The treating physician will select treatment as part of usual care, independently of study participation. The study will not assign treatment.

Participants will be followed for 12 months, with assessments at baseline, 6 months, and 12 months. The main outcome is the change in percentage total body fat measured by dual-energy X-ray absorptiometry, also called DXA, between baseline and 12 months. The study will assess whether the reduction in body fat with weekly treatment differs from that with daily treatment.

Other assessments will include lean body mass, growth, waist measurements, blood pressure, glucose and lipid metabolism, carotid artery wall thickness, bone mineral density, pubertal development, bone age, IGF-1 concentrations, and adverse events. No biological samples will be stored for research.

02

Conditions studied

  • Pediatric Growth Hormone Deficiency

Keywords

  • Pediatric growth hormone deficiency
  • Long-acting growth hormone
  • Body composition
  • Percentage body fat
  • Cardiometabolic health
  • Real-world evidence
03

In context

Lead sponsor

Fundació Sant Joan de Déu is the lead sponsor of 72 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children and adolescents aged 3 to 16 years with growth hormone deficiency who attend participating pediatric endocrinology departments in Spain and are initiating either weekly long-acting growth hormone or daily recombinant human growth hormone in routine clinical practice. Eligible candidates will be identified during routine clinical visits and invited to participate.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 3 and 16 years.
  • Diagnosis of growth hormone deficiency according to standard clinical practice in Spain and the applicable Spanish Ministry of Health criteria.
  • Growth hormone treatment approved by the relevant local authorities and institution.
  • Initiation of treatment with long-acting growth hormone or daily recombinant human growth hormone.

Exclusion criteria

Exclusion Criteria:

- Recombinant human growth hormone prescribed for an indication other than growth hormone deficiency.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
110 participants (estimated)
Patient registry
No

Groups and cohorts

  • Weekly Long-Acting Growth Hormone

    Children and adolescents with growth hormone deficiency initiating once-weekly somatrogon as prescribed in routine clinical practice. Treatment selection, initiation, dosing, and subsequent modifications are determined by the treating physician independently of study participation.

    Drug: Long-Acting Growth Hormone (LAGH)

  • Daily Recombinant Human Growth Hormone

    Children and adolescents with growth hormone deficiency initiating daily somatropin as prescribed in routine clinical practice. Treatment selection, initiation, dosing, and subsequent modifications are determined by the treating physician independently of study participation.

    Drug: Human recombinant growth hormone

Interventions

  • LAGH administered by subcutaneous injection once weekly as part of routine clinical care. Prescribed doses and dose adjustments will be determined by the treating physician and recorded by the study. Treatment is not assigned by the protocol.

    Also known as: NGENLA, Somatrogon

  • Human recombinant growth hormone administered by daily subcutaneous injection as part of routine clinical care. Prescribed products, doses, and dose adjustments will be determined by the treating physician and recorded by the study. Treatment is not assigned by the protocol.

    Also known as: Somatropin, Genotonorm, Omnitrope, Norditropin

06

What researchers measure

Primary outcomes

  1. Change in Percentage Total Body Fat

    Change in percentage total body fat measured by dual-energy X-ray absorptiometry (DXA), calculated as the 12-month value minus the baseline value and expressed in percentage points. Percentage total body fat is calculated as total fat mass divided by total body mass, multiplied by 100. Negative changes indicate a reduction in percentage total body fat. The adjusted between-cohort difference in change, defined as long-acting growth hormone minus daily recombinant human growth hormone, will be evaluated.

    Time frame: Baseline and 12 months

Secondary outcomes

  1. Change in Lean Body Mass

    Change in lean body mass measured by DXA, calculated as the 12-month value minus the baseline value and expressed in kilograms.

    Time frame: Baseline and 12 months

  2. Change in body mass index standard deviation score (BMI-SDS)

    Change in age- and sex-standardized BMI-SDS from baseline to 12 months. Weight and height will be used to calculate BMI-SDS based on World Health Organization tables.

    Time frame: Baseline and 12 months

  3. Change in height standard deviation score (SDS)

    Change in height SDS from baseline to 12 months. Height will be used to calculate BMI-SDS based on World Health Organization tables.

    Time frame: Baseline and 12 months

  4. Change in Waist Circumference

    Change in waist circumference from baseline to 12 months, expressed in centimeters.

    Time frame: Baseline and 12 months

  5. Change in Waist-to-Hip Ratio

    Change in waist circumference divided by hip circumference from baseline to 12 months. The ratio is dimensionless.

    Time frame: Baseline and 12 months

  6. Change in Systolic Blood Pressure

    Change in systolic blood pressure from baseline to 12 months, expressed in mmHg.

    Time frame: Baseline and 12 months

  7. Change in Diastolic Blood Pressure

    Change in diastolic blood pressure from baseline to 12 months, expressed in mmHg.

    Time frame: Baseline and 12 months

  8. Change in Fasting Glucose Concentration

    Change in fasting blood glucose concentration from baseline to 12 months.

    Time frame: Baseline and 12 months

  9. Change in Fasting Insulin Concentration

    Change in fasting blood insulin concentration from baseline to 12 months.

    Time frame: Baseline and 12 months

  10. Change in HOMA-IR

    Change in the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting glucose and insulin concentrations, from baseline to 12 months.

    Time frame: Baseline and 12 months

  11. Change in Total Cholesterol Concentration

    Change in total cholesterol concentration from baseline to 12 months.

    Time frame: Baseline and 12 months

  12. Change in LDL Cholesterol Concentration

    Change in LDL cholesterol concentration from baseline to 12 months.

    Time frame: Baseline and 12 months

  13. Change in HDL Cholesterol Concentration

    Change in HDL cholesterol concentration from baseline to 12 months.

    Time frame: Baseline and 12 months

  14. Change in Triglyceride Concentration

    Change in Triglyceride concentration from baseline to 12 months.

    Time frame: Baseline and 12 months

  15. Change in Change in Carotid Intima-Media Thickness

    Change in carotid intima-media thickness measured bilaterally by high-resolution ultrasound at baseline and 12 months, expressed in millimeters.

    Time frame: Baseline and 12 months

  16. Change in Bone Mineral Density Z-Score

    Change in bone mineral density Z-score measured by DXA from baseline to 12 months.

    Time frame: Baseline and 12 months

  17. Change in Height Standard Deviation Score

    Change in height standard deviation score (height SDS) from baseline to 12 months.

    Time frame: Baseline and 12 months

  18. Change in Growth Velocity Standard Deviation Score

    Change in growth velocity standard deviation score from baseline to 12 months.

    Time frame: Baseline and 12 months

  19. Change in Bone Age Minus Chronological Age

    Change in the difference between bone age and chronological age from baseline to 12 months, expressed in years. Bone age will be assessed by manual reading using the Greulich and Pyle atlas.

    Time frame: Baseline and 12 months

  20. Change in IGF-1 standard deviation score

    Change in insulin-like growth factor 1 (IGF-1) standard deviation score from baseline to 12 months.

    Time frame: Baseline and 12 months

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No — Individual participant data sharing with external researchers is not planned under the current protocol. Any future third-party data communication would require prior institutional assessment and authorization. The protocol limits such communication to aggregated data from which participants cannot reasonably be identified.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jun 2028, 19 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Nov 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941518
Lead sponsor
Fundació Sant Joan de Déu
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Marta Ramon Krauel, MD PhD
Contact
marta.ramon@sjd.es
+34 932 804 000 ext. 71702

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion